Discussions between the boards of NextCell Pharma AB (publ) (“NextCell”) and Idogen AB (publ) (“Idogen”) (together “The companies”) regarding a possible merger, are still ongoing. Further information will be published no later than the opening of trading on Wednesday, 08 May 2019.
The companies have initiated a limited customary, legal, financial and technical/scientific due diligence. At the same time, discussions are taking place between the boards of the Companies. Additionally, the merger if implemented, will take place through an exchange offer from NextCell with consideration in NextCell shares, the exchange relationship or other conditions have not yet been established. NextCell will publish additional information, no later than before the opening of trading on Wednesday, 08 May 2019.
This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation. The information was provided by the below contact person for publication on 06 May 2019.
Stay up to date with the latest development in NextCell Pharma
For more information about NextCell Pharma AB, please contact:
Mathias Svahn, CEO
Sofia Fredrikson, CFO
Phone: 08-735 5595